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Introduction
Anaesthesiologists have been concerned about the po-
tential renal toxicity of inhaled anaesthetic agents since
1966, when Crandell et al. [1] described nephrotoxicity
associated with methoxyflurane anaesthesia. A single ob-
servation of vasopressin-resistant polyuric renal insuffi-
ciency in a patient after methoxyflurane anaesthesia for
abdominal surgery was reported. This was followed by an
enormous number of anecdotal reports as well of clinical
studies documenting that renal failure following methoxy-
flurane anaesthetics, in fact, was not a rare event.
Developments of animal models and clinical studies
established that the condition was dose related and sec-
ondary to biotransformation of methoxyflurane to inor-
ganic fluoride. Subsequently, extensive studies were un-
dertaken to further characterise the pathomechanisms
responsible for this observation which included a broad
range of severity of the abnormalities: from mild cases
with only minor and transient increases of markers of
reduced renal function such as serum creatinine and
blood urea nitrogen up to severe courses of polyuric fail-
ure requiring dialysis or even leading to death due to acute
renal failure.
Degradation of methoxyflurane by hepatic cytochrome
P450 isoenzymes produces considerable amounts of inor-
ganic fluoride ions which can subsequently be detected in
the circulating blood. Because evidence of methoxyflu-
rane renal dysfunction was not observed when peak fluo-
ride concentrations were less than 50 ÌM, this concentra-
tion was considered to be the threshold of fluoride neph-
rotoxicity. The hypothesis of a 50-ÌM threshold was later
extended to all inhaled anaesthetics and clinical approval
was only sought for those substances for which liberation
of fluoride was not part of their metabolism.
The hypothesis that it were indeed the elevated serum
fluoride concentrations which were responsible for post-
operative renal damage was based on the following no-
tions: (1) There was a fairly well correlation of postopera-
tive peak serum fluoride concentrations with the degree of
renal dysfunction in humans [2]. (2) A similar type of
vasopressin-resistant polyuric renal insufficiency was re-
produced by intraperitoneal application of fluoride in
Fischer 344 rats [3]. (3) Inhibition by fluoride ions of a
variety of enzyme systems including those mediating anti-
diuretic hormone effects [4]. As a consequence, the renal
injuries seen in surgical patients following methoxyflu-
rane anaesthesia led to withdrawal of this anaesthetic
from clinical use. Since that time every new halogenated
inhalational anaesthetic was extensively studied in ani-
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mal models as well as in human studies to identify – if
present – its potential for producing changes in renal func-
tion and nephrotoxicity.
Sevoflurane is a relatively new inhalational anaesthetic
which was introduced into clinical practice in Europe and
North America in 1994/95. Its excellent pharmacokinetic
profile in combination with its pleasant smell facilitated
seek for clinical approval. However, with regard to renal
function sevoflurane is still a controversially discussed
agent for two reasons: (1) Hepatic metabolism of sevoflu-
rane releases inorganic fluoride. Albeit total metabolism
and hence resulting serum fluoride concentrations are less
than those observed with methoxyflurane, approximately
7% of surgical patients will postoperatively face serum
concentrations above the nephrotoxic threshold of 50 ÌM.
(2) A small portion of sevoflurane is degraded to com-
pound A by the carbon dioxide absorbents integrated into
the circle systems of all modern anaesthesia machines.
Compound A has been shown to produce nephrotoxicity
in rats. The intention of this paper is to review the own
investigations in combination with further human and
animal studies from other authors with respect to the
potential of sevoflurane for producing nephrotoxicity.
Animal Studies
Renal Perfusion
A well investigated factor leading to postoperative
renal dysfunction is hypoperfusion during the periopera-
tive period. Many drugs including anaesthetic agents have
been shown to induce hypoperfusion and this – alone or in
combination with other noxious stimuli – could easily
serve as an alternative hypothesis explaining a deteriora-
tion of renal function as seen after methoxyflurane.
Therefore, maintenance of renal blood flow is a prerequi-
site for use of all modern anaesthetic agents and also,
these agents should not interfere with principles of blood
flow regulation, i.e. autoregulation perfusion should be
maintained.
To rule out an interference with blood flow regulation,
we assessed the effects of sevoflurane on renal perfusion
in Sprague-Dawley rats. Animals were anaesthetised with
different concentrations of sevoflurane and perfusion was
assessed by radioactive microsphere technique. At mean
arterial pressures within the autoregulated range perfu-
sion was well maintained with sevoflurane and this was
also the case with isoflurane. Constant perfusion was due
to a decrease in vascular resistance which compensated
the reduced perfusion pressure. When arterial pressure
Fig. 1. Changes in renal blood flow (RBF) and renal vascular resis-
tance (RVR) in rats during sevoflurane (Sevo) and isoflurane (Iso)
anaesthesia. Control denotes baseline values during infusion of i.v.
chloralose. Concentrations of sevoflurane and isoflurane were ad-
justed to maintain stable haemodynamic parameters, i.e. equal mean
arterial pressures. Measurements were done under normotensive
(MAP 70) and hypotensive conditions (MAP 50). Values are given as
means B SEM. MAP = mean arterial pressure in mm Hg. * p ! 0.05
vs. control. Data from [5].
was lowered below the autoregulated range, perfusion
started to decrease (fig. 1). Thus, regulation of perfusion
did not differ from the awake physiologic state and the
obvious conclusion from these experiments was that there
was no genuine negative effect on blood flow [5].
Inorganic Fluoride
Inorganic fluoride serum concentrations in rats during
and after sevoflurane anaesthesia were increased over the
preoperative control but were only about half the concen-
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trations seen after methoxyflurane. In surgical patients
serum fluoride levels after methoxyflurane reached from
50–80 ÌM to over 175 ÌM after 2.5–3.0 and 7–9 MAC Wh,
respectively [6]. In contrast, after sevoflurane fluoride lev-
els were reported to be 29.3 B 1.8 ÌM after 1.0–7.0
MAC Wh [7] and 42.5 B 4.5 Ìmol/l after long-term (13.4 B
0.9 h) anaesthesia [8]. In both studies, peak serum inor-
ganic fluoride levels in excess of 50 ÌM were obtained in
a significant number of patients (5/25, 5/10). Phenobar-
bital induction of hepatic enzyme activity yielded inor-
ganic fluoride levels after sevoflurane comparable to
those after methoxyflurane but without enzyme induc-
tion [9]. However, while methoxyflurane produced neph-
rotoxicity in the Fisher 344 rat, sevoflurane was devoid
of such problem [10].
While the rates of sevoflurane and methoxyflurane
defluorination by hepatic microsomes were comparable
in vitro, the urinary fluoride excretion after sevoflurane
amounted to only one third to one fourth of that after
methoxyflurane [10]. The conclusion of these diverging
observations is that beside hepatic metabolism to inor-
ganic fluoride there must be another additional factor
contributing to metabolism of methoxyflurane and anoth-
er source for liberation of fluoride ions. This additional
factor might also explain the diverging consequences for
renal function.
Patient Studies
Inorganic Fluoride
Sevoflurane metabolism by the human hepatic cyto-
chrome P450 system ranges between 3 and 7% of total
uptake. Two major degradation products have been iden-
tified, hexafluoroisopropanol and inorganic fluoride. The
degree of sevoflurane metabolism is usually estimated
from clearance of these products [11]. Since its rate of deg-
radation is higher, sevoflurane metabolism results in high-
er peak serum fluoride levels as compared to isoflurane,
halothane and, enflurane [12]. Nevertheless, due to its low
blood gas partition coefficient and hence its rapid elimi-
nation at the end of anaesthesia average total exposition
to fluoride is lower after sevoflurane than after enflurane.
Hexafluoroisopropanol is rapidly eliminated from the
body and devoid of toxic problems.
In the clinical setting, it must be expected that about
7% of anaesthetised patients will have peak serum fluo-
ride concentrations in excess of 50 ÌM, which is the pre-
sumed threshold for nephrotoxicity. In one study looking
specifically at surgical cases of prolonged duration, five
Fig. 2. Mean plasma inorganic fluoride ion concentrations during
and after sevoflurane or enflurane anaesthesia. Measurements were
obtained in patients with a stable preexisting renal insufficiency.
Peak values and concentrations during the first postoperative day
were significantly higher in sevoflurane anaesthetised patients. Mean
values from all patients are presented. Data from [15].
out of ten patients had serum inorganic fluoride concentra-
tions exceeding 50 ÌM after sevoflurane. This study also
reported a positive correlation between serum inorganic
fluoride concentration and the applied sevoflurane dose
[8]. There was good correlation between the total dose of
sevoflurane (MAC Wh) and either total fluoride production
or peak fluoride concentration. Such a relationship was
absent in the isoflurane group (n = 25/25) [13].
Also another study reported serum inorganic fluoride
concentrations above 50 ÌM regularly after prolonged
(17 h) sevoflurane anaesthesia [14]. To date there is an
ample number of publications addressing this problem.
The most remarkable finding of all of these investigations
is that renal problems did not occur more often in patients
having fluoride levels above the presumed nephrotoxic
threshold as compared to patients remaining below.
Patients with chronically reduced renal function are at
an increased risk for suffering a further deterioration of
function perioperatively. Therefore, it is a prerequisite for
every new drug to be approved for clinical use that its
safety in this patient population has been documented.
Vice versa, such patients might provide a sensitive model
for evaluating the consequences of increased levels of
plasma inorganic fluoride on renal function since even
small changes in function must be expected to be followed
by marked alterations in laboratory tests of renal func-
tion.
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Fig. 3. Serum creatinine measurements in patients with increases above the preoperative control of 20% or more.
Measurements were obtained before (0 h), at the end of anaesthesia (End), and in the postoperative course. Only
patients with a preexisting stable renal insufficiency were included. Increases in creatinine were more likely to occur
in the late postoperative period than at days 1 or 2. Also, the likelihood for an increase was not higher after sevoflurane
than after enflurane. These results suggest that the observed increases were independent of the perioperatively
elevated fluoride concentrations which had been significantly higher in patients with sevoflurane (see fig. 2). Data
from [15].
To address this problem, we recently randomised sur-
gical patients with a chronic impairment of renal function
(defined as stable elevation of serum creatinine concen-
tration above 1.5 mg/dl) to receive either enflurane or
sevoflurane anaesthesia. Comparisons were based on ef-
fects on renal function as measured by changes in urine
and serum variables. Despite a significantly higher peak
serum inorganic fluoride concentration in the sevoflurane
group there was no effect on renal function as shown by
standard test in either group (fig. 2) [15]. In fact, renal
function remained fairly stable in both groups. Only few
patients had increases in their creatinine (fig. 3) or blood
urea nitrogen concentrations but there was absolutely no
difference in incidence among anaesthetics.
This study of our group provided further evidence
against a significant role of circulating inorganic fluoride
for producing the type of renal failure which was observed
following methoxyflurane. While there was a close rela-
tionship of the resulting fluoride concentrations with
renal injury after methoxyflurane, this relationship is
absent with sevoflurane and enflurane. Cause or coinci-
dence? The results from this and from other clinical trials
strengthened the belief that circulating fluoride was not a
major pathogenic factor for the well described renal prob-
lems after methoxyflurane.
Pathomechanism of Fluoride Nephrotoxicity
Cytochrome P450 isoforms are manifold and vary in
their concentrations and activities from organ to organ.
Kharasch and co-workers [16] studied defluorination of
sevoflurane, enflurane, methoxyflurane, and isoflurane
by human liver microsomes in vitro. Cytochrome P 450
2E1 was identified as the predominant human hepatic
enzyme responsible for metabolism of sevoflurane. This is
in contrast to methoxyflurane which was also metabolised
by P450 isoforms 1A2, 2C9/10, and 2D6 [16]. Reduced
release of inorganic fluoride from sevoflurane following
administration of disulfram, a potent inhibitor of cyto-
chrome P 450 2E1, supports absence of metabolism by
other isoforms [17].
Methoxyflurane undergoes extensive renal defluorina-
tion in animals, at a rate almost half that occurring in the
liver. In contrast, sevoflurane undergoes little renal de-
fluorination. Methoxyflurane is metabolised by several
P450 isoforms, whereas sevoflurane is metabolised pre-
dominantly by P450 2E1 [11]. Thus, in humans, mean-
ingful renal metabolism may be uniquely associated with
methoxyflurane. Therefore, renal (not hepatic) defluori-
nation of methoxyflurane, but not of sevoflurane, under-
lies the nephrotoxicity of methoxyflurane but not of sevo-
flurane.
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Fig. 4. Inspiratory compound A concentrations during sevoflurane
anaesthesia (2 vol %) for laparoscopic cholecystectomy under low-
flow conditions. Two different carbon dioxide absorbents were used:
Sodasorb® (Absorbent 1) and Soda Lime® (Absorbent 2). Albeit
absorbent 1 is free of the strong alkali potassium hydroxide, degrada-
tion of sevoflurane is more pronounced and this results in higher
compound A levels. Mean values B SEM are given. Data from [32].
Compound A
Compound A (fluoromethyl 2,2-difluoro-1-(trifluoro-
methyl)-vinyl-ether) does not originate from hepatic me-
tabolism of sevoflurane but from a chemical reaction with
strong alkali components of carbon dioxide absorbents
(potassium- and sodiumhydroxide). The formation and
accumulation of this olefin, for simplicity called com-
pound A, in rebreathing anaesthesia circuits is especially
high with low fresh gas flows. The ubiquitous presence of
rebreathing systems and the economic and ecological
pressures for using low fresh gas flows mandate absence of
any type of toxicity from this source in humans at all
potential scenarios.
Animal Studies
Wistar rats exposed to compound A by inhalation of
different concentrations ranging from 0 to 400 ppm for a
3-hour exposure showed histological signs of renal injury
(necrosis of the outer strip of the outer medulla) at con-
centrations of 50 ppm and above. The threshold for neph-
rotoxicity in rats thus reaches the range of values for com-
pound A which is also attained in clinical practice in some
patients [18] but not regularly during routine surgery of
short to intermediate duration (fig. 4).
Compound A-derived cysteine S-conjugates are sub-
strates for renal beta-lyase in rats [19]. Further enzymatic
degradation results in highly reactive acylating agents
which covalently bind to a variety of macromolecules
within the renal tubular cells [20]. This binding again
results in molecular destruction, cellular necrosis and the
type of renal damage seen in various rat models (increases
of blood urea nitrogen and creatinine, glucosuria, protein-
uria).
Alleviation of compound A-induced proteinuria by
aminooxyacetic acid, a competitive inhibitor of renal cys-
teine conjugate ß-lyase, suggests that glutathione conju-
gate formation, subsequent processing to cysteine conju-
gates, and cysteine conjugate metabolism by renal ß-lyase
indeed is an important factor in the pathogenesis of com-
pound A-mediated nephrotoxicity [21]. High-dose acet-
aminophen treatment producing glutathione depletion
led to renal cortical injury on exposure to 100 ppm com-
pound A [22]. A study with inhibitors of renal organic
anion transport and S-conjugate uptake, of Á-glutamyl
transferase, an enzyme that cleaves glutathione conju-
gates to cysteine conjugates, suggests that renal uptake of
compound A-glutathione or compound A-cysteine conju-
gates and cysteine conjugate metabolism by renal ß-lyase
mediate at least in part compound A nephrotoxicity in
rats [23].
The latter study was conducted with intraperitoneally
administered compound A and this was critizised but a
study with inhaled compound A showed comparable
results [24].
It is important to stress that species differences are
very important for compound A nephrotoxicity. While
there is ample evidence that compound A is toxic in rats
and other rodents, this type of damage was not repro-
duced in other species including dogs and monkeys. E.g. a
study in beagles showed no increase in the excretion of
renal tubular enzymes during and after repeated low-flow
sevoflurane anaesthesia [25]. It has been shown that tubu-
lar cell ß-lyase activity in the latter animal species, as well
as in man, is much lower than in rodents. This results in a
far lower formation of highly reactive compound A conju-
gates and, as a consequence, in a lower likelihood of renal
injury.
Human Studies
As already stated above, compound A is the only deg-
radation product detected in significant amounts in
anaesthesia circuits during long-duration, low-flow sevo-
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flurane anaesthesia. In an early Japanese study, the indi-
vidual maximum concentrations of this breakdown prod-
uct ranged between 13.6 and 35.1 ppm (mean value: 24.3
B 2.4 ppm) [26]. This study as well as a large number of
further studies from countries all over the world failed to
document any relevant effect of compound A on renal
function. For assessing renal injury these studies either
used the standard laboratory parameters for reduced renal
function (i.e. creatinine, blood urea nitrogen, excretion of
protein or glucose), or the presumed more sensitive mark-
ers of renal injury (excretion of tubular intracellular
enzymes such as NAG).
Exposure of children to sevoflurane may be higher
than in adults because of their higher MAC values and
hence the higher sevoflurane concentrations needed in-
traoperatively. There is certainly also a positive correla-
tion for compound A formation with body surface area in
children but the absolute exposition to compound A is not
higher than in adults. Correspondingly, there was no evi-
dence of renal dysfunction in children [27].
To date, there is only one study available claiming a
potential of compound A for producing renal injury in
humans. A relatively small study performed in healthy
volunteers reported transient elevations of what the au-
thors called sensitive markers of renal dysfunction. They
reported post-anaesthetic albuminuria indicating injury
of the glomerulus, glucosuria and increased urinary ·-
GST as signs of proximal tubular injury, and increased
urinary -GST indicating distal tubular injury. However,
serum routine parameters of renal function such as creati-
nine, blood urea nitrogen or the ability to concentrate
urine (vasopressin test) remained unchanged [28].
The authors in addition believe that there is a thresh-
old for compound A nephrotoxicity in man. This is in-
ferred from a follow-up study in which post-anaesthetic
albuminuria, increased urinary ·-GST and slightly in-
creased serum creatinine occurred after 4 h but not after
2 h of anaesthesia with 1.25 MAC sevoflurane or about
40 ppmh compound A. It was concluded that the thresh-
old for inducing renal damage in humans is between 80
and 160 ppm Wh compound A which is similar to the
threshold found in rats [29]. However, attempts by other
authors to copy the results of these studies failed. Frink et
al. [27] while using the same experimental protocol and
the same laboratory tests were unable to duplicate the
type of injury reported by Eger et al. [28, 29]
There is no good explanation for the puzzling results
obtained in one single lab. It must not be forgotten that
even prolonged (610 h) sevoflurane (high or low fresh gas
flow) or isoflurane anaesthesia increased urinary excre-
Fig. 5. Serum creatinine concentrations in patients with a stable pre-
operative renal insufficiency (11.5 mg/dl). Patients underwent gen-
eral anaesthesia for surgery with either low-flow sevoflurane or iso-
flurane. Sevoflurane but not isoflurane patients had been exposed to
compound A intraoperatively. Stable creatinine concentrations in
the postoperative course indicate that renal function was not affected
by compound A. Data submitted for publication by Conzen et al.
tion of glucose, albumin, protein, and N-acetyl-ß-D-gluco-
saminidase to the same extent. There were no significant
differences between the three groups at any time point
after anaesthesia. Despite an average compound A uptake
of 277 B 120 ppm Wh during low-flow sevoflurane anaes-
thesia the effect on the kidney was the same as with high-
flow sevoflurane and low-flow isoflurane anaesthesia [30].
These observations certainly are a strong argument
against the existence of a nephrotoxic threshold as pro-
posed by Eger and coworkers.
A just finished study performed in our department was
directed towards patients with chronic renal impairment.
For this purpose chronic impairment was again defined
as stable preoperative elevation of serum creatinine
61.5 mg/dl. All patients were randomised to receive low-
flow anaesthesia of at least 3 h duration with either sevo-
flurane or isoflurane. As the results indicate, there were
absolutely no differences in routine renal function param-
eters after low-flow sevoflurane and low-flow isoflurane
anaesthesia (fig. 5). We also measured sensitive markers
of renal injury as ß2-microglobulin, N-acetyl-ß-D-gluco-
saminidase, ·-, -GST in a subgroup of patients. Again
there were no differences between groups. Therefore, we
can conclude from this study as well as from earlier pub-
lished data that the sevoflurane breakdown product com-
pound A is not a relevant toxin in humans.
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Mechanism for Compound A Toxicity in
Rodents
Bioactivation of many haloalkenes, such as compound
A, results in localised cytotoxicity in renal proximal
tubules. The complex scheme, collectively called ß-lyase
pathway, has been elucidated for myriads of haloalkenes.
Results from recent investigations in rats provide evi-
dence that certain key enzymes of the ß-lyase pathway
also mediate compound A nephrotoxicity [23].
Mediation of compound A nephrotoxicity by the renal
cysteine conjugate ß-lyase pathway obviously has impor-
tant implications regarding interspecies differences in
compound A effects. Human renal ß-lyase activity and ß-
lyase metabolism of compound A cysteine conjugates are
approximately 8–30 times less than that in rat kidney
[31]. It is speculated that far higher concentrations of
compound A than those observed in clinical practice
would be required to produce a clinically relevant injury
in surgical patients. This interspecies difference in en-
zyme activities could easily explain the obvious differ-
ences of compound A toxicity – well documented injury
in the rat and in other rodents, while absence of toxicity in
humans.
Conclusion
A large variety of inhalation anaesthetics with the
potential for use in humans have been synthesised during
the past decades. However, only a small portion has
reached clinical approval. Many substances were with-
drawn already at early stages of approval because of
potential toxicity and other risk factors. This also was
partly the case with sevoflurane. Two factors delayed its
approval: (1) sevoflurane is partly metabolised by hepatic
cytochrome P450 to inorganic fluoride. The clinical expe-
rience with methoxyflurane suggested that elevated fluo-
ride concentrations may be nephrotoxic. (2) Sevoflurane
undergoes dehydrofluorination by carbon dioxide ab-
sorbers of anaesthesia machines, producing small quanti-
ties of degradation products. Compound A is quantita-
tively predominant and this product has been shown to be
nephrotoxic in rats.
Both factors, inorganic fluoride and compound A have
been extensively studied in the years prior to approval for
human use. To date, there is no evidence for any type of
renal injury associated with this anaesthetic. This implies
that application of results concerning toxicity of halogen-
ated anaesthetic agents to another species or to another
anaesthetic must be done with great caution. Our clinical
studies in patients with stable renal insufficiency have
clearly shown that even renal risk patients can be anaes-
thetised with sevoflurane as safely as with any other mod-
ern halogenated anaesthetic.
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